⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

April 29, 2024Journal of Endocrinological InvestigationOpen Access

Real-world use of oral versus subcutaneous semaglutide in a cohort of type 2 diabetic patients: which option to which patient?

Caterina Formichi Walter Baronti Giovanni Gennaro Mauro Ceroni Laura Nigi Loredana Rizzo Francesco Dotta

View Full Paper

Ask AI

Bookmark

Share

Abstract

To evaluate the variables influencing the therapeutic choice toward oral versus subcutaneous semaglutide in a cohort of diabetic subjects.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Formichi et al. (2024) studied this question.

synapsesocial.com/papers/68e6d055b6db64358764dd7d https://doi.org/10.1007/s40618-024-02369-4

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts2024 · 27 citations
2Retrospective Comparative Study of Oral Versus Subcutaneous Semaglutide in Patients with Type 2 Diabetes Mellituscohort · 2026
3Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study2024 · 18 citations
4Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 DiabetesCohort Study · 2023 · 27 citations
5Oral vs. Subcutaneous Semaglutide for Obesity Treatment: A Systematic Review of Efficacy, Safety, and Patient-Oriented OutcomesMeta-Analysis · 2026

More related papers

Effectiveness of oral semaglutide on glucose control and body weight up to 18 months: a multicenter retrospective real-world study2024
Oral Semaglutide in Routine Clinical Practice: Characteristics of People with Type 2 Diabetes Started on the Drug and Changes in Their Clinical Parameters after 24 Weeks of Treatment2024
Efficacy and Safety in a Real-World Study of the New Oral Formulation of Semaglutide in Patients with Chronic Kidney Disease and Type 2 Diabetes Mellitus2024

More from Journal of Endocrinological Investigation

Therapeutic errors associated with thyroid medications in non-healthcare facility settings reported to United States poison centers, 2000–2024Wed,
Clinical and metabolic characteristics of acquired partial lipodystrophy: insights from a multicenter studyMon,